Skip to search formSkip to main contentSkip to account menu

Carboplatin

Known as: CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum 
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two… 
National Institutes of Health

Related topics

Related topics

44 relations

Broader (2)

Antineoplastic AgentsCisplatin

Narrower (12)

BIC protocolCIV protocolCarbo-MVE protocolDWA 2114
CAC protocolCTCb regimenCarboplatin 10 MG/ML Injectable SolutionCarboplatin/Neovastat/Paclitaxel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
Highly Cited
2010
Highly Cited
2010
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Highly Cited
2006
Highly Cited
2006
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four…
BACKGROUND To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan… 
Highly Cited
2006
Highly Cited
2006
Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin
The goal of this study was to determine the ability of the major copper influx transporter CTR1 to mediate the cellular… 
Review
2006
Review
2006
The Discovery and Development of Cisplatin
Cisplatin is currently one of the most widely used anticancer drugs in the world. The unlikely events surrounding the discovery… 
Review
2006
Review
2006
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Review
2006
Review
2006
Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Review
2004
Review
2004
Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
Cisplatin continues to play a central role in cancer chemotherapy in spite of its toxicity. It is used as first-line chemotherapy… 
Highly Cited
2000
Highly Cited
2000
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
PURPOSE To determine the side effects and feasibility of cisplatin and carboplatin each in combination with paclitaxel as front… 
Highly Cited
1992
Highly Cited
1992
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
PURPOSE The Southwest Oncology Group (SWOG) conducted a randomized comparison of cisplatin plus fluorouracil (5-FU) and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)